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Abstract: There has been an ample interest in delivery of therapeutic molecules using live 
cells. Oral delivery has been stipulated as best way to deliver live cells to humans for therapy. 
Colon, in particular, is a part of gastrointestinal (GI) tract that has been proposed to be an oral 
targeted site. The main objective of these oral therapy procedures is to deliver live cells not 
only to treat diseases like colorectal cancer, inﬂ  ammatory bowel disease, and other GI tract 
diseases like intestinal obstruction and gastritis, but also to deliver therapeutic molecules for 
overall therapy in various diseases such as renal failure, coronary heart disease, hypertension, 
and others. This review provides a comprehensive summary of recent advancement in colon 
targeted live bacterial cell biotherapeutics. Current status of bacterial cell therapy, principles of 
artiﬁ  cial cells and its potentials in oral delivery of live bacterial cell biotherapeutics for clinical 
applications as well as biotherapeutic future perspectives are also discussed in our review.
Keywords: biotherapeutics, probiotic, microcapsules, gastrointestinal tract, colon, oral delivery, 
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Introduction
In the past decade the ﬁ  eld of gastrointestinal (GI)-related diseases has received ample 
interest. Physicians treating GI disorders had to face new challenges during recent 
years. On the one hand GI-related problems are growing rapidly within the population, 
especially in older patients and those with the following disorders: diarrhea, irritable 
bowel disease, pouchitis, Crohn’s disease or ulcerative pouchitis; on the other hand; 
efﬁ  cient and safe treatment has yet to arrive. By increasing the cost of medical care there 
has been an obvious need for a more reliable treatment method of higher efﬁ  cacy. GI 
research is constantly working on exploring new techniques, designing new systems, 
and discovering new ways of delivering certain drugs of interest to the target organs. 
In particular, GI cancers pose major public health problems in the United States as 
well as most western countries. There are six main diseases associated with colon: 
Crohn’s disease (ileitis or enteritis), diverticulitis, ulcerative colitis, irritable bowel 
syndrome (IBS), colonic dismotility, and colon cancer.
A signiﬁ  cant health care burden is associated with IBS, with increased out-patient 
services, abdominal and pelvic surgeries, and GI- and non-GI-related physician visits 
and health care costs. Functional GI disorders such as functional dyspepsia, IBS, and 
other chronic medical conditions like gastroesophageal reﬂ  ux disease and asthma 
impact signiﬁ  cantly the patient’s health-related quality of life. Impaired health-related 
quality of life has been demonstrated, in particular, in patients with moderate to severe 
disease seen in referral settings. Although the quality of life appears to improve in 
treatment responders, or correlates with symptom improvement, with at least some 
treatment modalities studied in functional gastrointestinal disorders it still required Biologics: Targets & Therapy 2008:2(3) 356
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further studies. The signiﬁ  cance of psychological factors 
such as early adverse life events or symptoms related to 
visceral perception such as pain and chronic stress further 
contribute to impairment of health-related quality of life 
in patients with functional GI disorders. The presence of 
extraintestinal symptoms appears to have a major if not 
greater impact on health care visits, excess health care costs, 
and health-related quality of life in patients with functional 
GI disorders (Chang 2004).
This review covers state of the art methods and technolo-
gies for targeted GI delivery of oral live cells, with in depth 
coverage of live cell biotherapeutics used in treatment of 
various GI disorders. In addition, the potential and limitations 
as well as future perspectives are discussed.
Colon, an ideal place for action 
of biotherapeutics molecules – 
overview of GI tract and its 
molecular basis
Esophagus, stomach, duodenum, small intestine (ileum), 
large intestine (colon), appendix, liver, gallbladder and 
pancreas all comprise a gut by forming a tube connection 
between mouth and anus through which food passes. GI 
tract (GIT) is a tubular passage made of muscle and mucous 
membrane that extends about 8.3 meters in length. Colon, a 
tube-like organ is made of 4 sections: the ascending colon, 
transverse colon, the descending colon, the sigmoid colon 
and it is about 1.5 to 2 meters long. Its primary function is 
to absorb water and salts from undigested foods and store 
the waste-products until excreted. The colon is viewed as the 
preferred absorption site for oral administration of protein 
and peptide drugs because of the relatively low proteolytic 
enzyme activities in the colon (Yang et al 2002).
The ﬂ  ora of the GIT in mammals is highly complex and 
diverse. The normal intestinal immune system is under a 
balance in which proinﬂ  ammatory and antiinﬂ  ammatory 
cells and molecules are carefully regulated to promote a 
normal host mucosal defense capability without destruction 
of intestinal tissue (Hahm et al 2001). Once this careful 
regulatory balance is disturbed, nonspeciﬁ  c stimulation 
and activation can lead to increased amounts of potent 
destructive immunological and inﬂ  ammatory molecules 
being produced and released. The concept of balance and 
regulation of normal mucosal immune and inﬂ  ammatory 
events is indicative of how close the intestine is to developing 
severe inﬂ  ammation. The normal intestinal mucosal immune 
system is constantly stimulated by lumenal contents and 
bacteria (MacDermott 1996). 95% of  bacteria residing in GIT 
are obligate anaerobes with species like: Biﬁ  dobacterium, 
Clostridium, Eubacterium, Fusobacterium, Peptococcus, 
Peptostreptococcus, and Bacteroides and 10% is made 
of facultative anaerobes: Lactobacillus, Escherichia coli, 
Klebsiella, Streptococcus, Staphylococcus, and Bacillus. It 
has been estimated that there are approximately 1012 viable 
bacteria per gram of large bowel content in humans, with the 
presence of at least 400 to 500 species (Simon and Gorbach 
1984; Berg 1996). The stimulatory molecules present in the 
intestinal lumen that activate and induce subsequent muco-
sal immunologic and inﬂ  ammatory events include bacterial 
cell wall products, such as peptidoglycans and lipopolysac-
charides, as well as other chemotactic and toxic bacterial 
products that are produced by the many different types of 
bacteria within the GIT (MacDermott 1996).
The complex intestinal human defense system consists 
of innate and adaptive immune systems, which further are 
composed of intraluminal breakdown like gastric acid, 
pancreatic enzymes and bile as well as prevention of adhesion 
like intestinal motility and mucus layer. The intestinal 
motility, when disturbed, may promote bacterial overgrowth. 
The layer of mucus holds an important nonimmune gut 
barrier role. It forms two compartments: viscoelastic gel 
and superﬁ  cial hydrosoluble layer which are composed of 
water, mucin glycoproteins and lipids. Mucus can also act as 
an antioxidant and counteract inﬂ  ammatory mediators and 
byproducts (Neutra and Forstner 1987; Lichtenberger 1995). 
Its main functions include physical and epithelial barrier with 
intercellular tight junctions and constant cell turnover, a site 
for glycoproteins to compete with gut surface for bacterial 
or antigen binding as well as a site which favors bacterial 
colonization.
The mucous layer and mucin production are qualitatively 
and quantitatively altered in many situations of intestinal 
stress, including the inﬂ  ammatory bowel diseases (IBD) 
(Neutra and Forstner 1987), ulcerative colitis (UC), and 
Crohn’s disease (Corﬁ  eld et al 2000). For example, in the 
active phase of the disease, UC patients exhibit reductions 
in the thickness of the colonic mucous layer, in the number 
of mucus-containing goblet cells, and in ex vivo analyzed 
MUC2 production (the main secreted-colonic mucin) (Faure 
et al 2005). The intricate system of digestive tract to restrict its 
potentially harmful contents is further made of the epithelial 
layer with presence of intercellular tight junctions as well as 
expression of adherence factors on the surface (Viswanathan 
and Hecht 2000). The tight junctions provide protection of 
the intercellular spaces and restrict the passage via the extra Biologics: Targets & Therapy 2008:2(3) 357
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cellular pathway. Any perturbation of the intestinal barrier 
may lead to promotion of bacterial adherence. For instance, 
a study revealed a redistribution of the tight junctional 
transmembrane protein upon infection with Campylobacter 
jejuni which is a leading cause of human enterocolitis and is 
associated with postinfectious complications, including IBS 
and Guillain-Barre syndrome (MacCallum et al 2005; Chen 
et al 2006c). The adherence factors are expressed on the 
surface of epithelial cells. For instance, Helicobacter pylori 
has been identiﬁ  ed as such agent which once attached to the 
epithelial surface initiates infection. Although a number of 
speciﬁ  c adhesins has been identiﬁ  ed, other H. pylori virulence 
factors may play a role in adherence to gastric epithelial cells 
directly or through interaction with other adhesions (Zhang 
et al 2002). The presence of adherence factors is genetically 
determined but the expression can be modiﬁ  ed (Ho et al 
2005). Pattern recognition receptors (PRRs) play a role in 
allowing innate immune cells to distinguish between “self” 
and microbial “nonself” based on the recognition of broadly 
conserved pathogen-associated molecular patterns (PAMPs) 
(Kabelitz and Medzhitov 2007). Toll-like receptors (TLRs) 
comprise a class of transmembrane PRRs which play a role 
in microbial recognition, induction of antimicrobial genes, 
and the control of adaptive immune responses (Werling and 
Jungi 2003).
Figure 1 summarizes brieﬂ  y the concept of TLRs. 
TLRs are expressed in epithelial cells of the skin, respira-
tory, intestinal, and genitourinary tracts that form the ﬁ  rst 
protective barrier to invading pathogens (Sandor and Buc 
2005). TLRs activate downstream effectors through adap-
tors that contain Toll/interleukin-1 receptor (TIR) domains, 
but the mechanisms accounting for diversiﬁ  cation of TLR 
effector functions are unclear (Häcker et al 2006). The 
adaptive immune system is composed of gut-associated 
lymphoid tissue (GALT) and epithelial cells. The cell-
mediated branch of the adaptive immune response relies 
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Figure 1 Schematic representation of molecular toll-like receptors (TLRs) of the human gastrointestinal (GI) tract which act as sensors and are the ﬁ  rst responders in the 
major pathway by which the immune system detects infection or damaged tissue. Their biological function makes them attractive targets for designing various biotherapeutic 
molecules for such disorders as inﬂ  ammation, infections, autoimmunity, allergies and cancer.Biologics: Targets & Therapy 2008:2(3) 358
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on mucosal T lymphocytes and the humoral defense is 
composed of B lymphocytes and plasma cells secreting 
IgA molecules. The lymphocytes are located in organized 
structures like Peyer’s patches and isolated lymphoid 
follicles. The follicle-associated epithelium (FEA) spans 
the lymphoid structures of Peyer’s patch and consists of 
cubical enterocytes (FEA cells) and M cells. M-cells are 
responsible for sampling of particulate microbial material 
(Hathaway and Kraehenbuhl 2000). It has been found that 
M cells get damaged and increased in inﬂ  amed human ileal 
mucosa (Cuvelier et al 1993). More detailed description 
of molecular composition of GIT is beyond the scope of 
this review.
Due to high complexity of the microbiota and the 
limitation of widely used culture-based techniques, the 
dynamic changes in the composition of the normal GIT 
microbial species in immunocompetent hosts during 
aging, between genders, and after experimental infection 
with microbial pathogens are still not well understood 
(Ge et al 2006).
Colon-speciﬁ  c drug delivery – 
methods and limitations
The old school colonic drug delivery approaches included 
four methods, namely, prodrugs, pH- and time-dependent 
systems, and microﬂ  ora-activated systems. The continuous 
effort to establish new improved techniques of drug delivery 
yielded methods like pressure-controlled colon delivery 
capsules (PCDCs), CODES, colonic drug delivery system 
based on pectin and galactomannan coating, and Azo 
hydrogels. These approaches bear features like improved 
in vivo site specificity, versatile drug release kinetics, 
feasibility of the manufacturing process and design ratio-
nale to accommodate different therapeutic needs. These 
have been extensively described by Yang and colleagues 
(2002). Other methods include: pro-drugs, timed-released 
systems, coating of pH-dependant polymer and the use of 
polysaccharides.
Novel approaches in colon-speciﬁ  c delivery system have 
been proposed like: a microbially triggered colon-targeted 
osmotic pump (MTCT-OP) (Liu et al 2007), TARGIT 
technology with application of pH-sensitive coatings onto 
injection-moulded starch capsules (Watts and Smith 2005), 
cross-linked microspheres of guar gum studied by Chourasia 
and Jain (2004) in delivery of metronidazole and nanopar-
ticles which are claimed to be able to deliver drugs to the 
inﬂ  ammation site in severe cases of IBD where state-of-the-
art delivery devices fail (Lamprecht et al 2005).
Various GI diseases 
and their treatment limitations
Collagenous colitis
Collagenous colitis (CC) is primarily a disorder of middle-aged 
women and is characterized on biopsy by increased subepi-
thelial collagen as well as increased inﬂ  ammatory cells in 
the lamina propria and increased intraepithelial lymphocytes. 
Approximately 10% of lymphocytic colitis patients have a 
positive family history of some type of inﬂ  ammatory intes-
tinal disease, including UC, Crohn’s disease, CC, and celiac 
disease. Lymphocytic colotis is a subtype of collagenous 
colitis and it is characterized by chronic nonbloody watery 
diarrhea. Therapy in lymphocytic colitis is less well studied, 
but the same medications are used with success, including 
budesonide and high dose bismuth subsalicylate (Lazenby 
2005). Other drugs used include prednisolone and Boswellia 
serrata extract. A study by Duncan and colleagues (1997) 
clearly implied that the treatment of patient with prednisolone 
may cause the collagenous colitis.
Diarrhea
Drug-induced diarrhea is a relatively frequent adverse 
event, accounting for about 7% of all adverse effects of drug 
therapy, being more frequent in the elderly because of factors 
related to the aging process itself and the higher frequency 
of drug therapy (Chassany et al 2000). More than 700 drugs 
have been implicated in causing diarrhea, which can appear 
a long time after the start of drug treatment, sometimes up 
to several months or years, and the diagnosis can be unrec-
ognized (Spreux et al 1993). In the case-control study by 
Fernandez-Banares and colleagues (2006) patients consumed 
a variety of drugs such as prednisone, diuretics, omeprazole, 
low-dose aspirin, bisphosphonates, and many more. The 
results revealed that the usage of selective serotonin reuptake 
inhibitors (SS-RIs) and statins signiﬁ  cantly related to the risk 
of chronic diarrhea (Fernandez-Banares et al 2006).
Microscopic colitis
Microscopic colitis is a term used to deﬁ  ne those entities 
characterized by chronic watery diarrhea, normal radiological 
and endoscopic appearance, and microscopic abnormali-
ties in the colon. The entity includes CC and lymphocytic 
colitis (LC) (Chang et al 2005). Various studies include the 
following treatments: bismuth subsalicylates, budesonide, 
prednisolone, Boswellia serata, cholestyramine, and 
5-aminosalicylic acid agents (Abdo and Beck 2003). Insofar, 
the treatment with budesonide looks promising, however, the Biologics: Targets & Therapy 2008:2(3) 359
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evidence for beneﬁ  t with bismuth subsalicylate is weaker. 
Moreover, the effectiveness of prednisolone, Boswellia 
serrata extract and other therapies for induction or mainte-
nance of remission of colitis is unknown and requires further 
study (Chande et al 2006).
Gastritis caused by Helicobacter pylori
Helicobacter pylori is a Gram-negative, spiral bacterium that 
colonizes the gastric mucosa of at least 50% of the world’s 
population and plays a causative role in the development of 
chronic gastritis as well as in gastric and duodenal ulcers 
(Velin et al 2005). This infection also represents a high risk 
factor in mucosa-associated lymphoid tissue lymphomas 
and gastric adenocarcinomas (Blaser and Parsonnet 1994; 
Czinn and Nedrud 1997). Treatment regiments to eliminate 
gastric H. pylori infection are based on the association of 
two antibiotics and an antisecretory agent, most often a 
proton pump inhibitor. In a single-center randomized study 
the effect of high-dose intravenous proton pump inhibitor 
(omeprazole) alone (group 1) with omeprazole in combi-
nation with a low-dose prostaglandin analog (misoprostol; 
group 2) on clinical outcomes in patients with aspirin/
nonsteroidal antiinflammatory drug (NSAID)-induced 
upper GI bleeding was compared (Yilmaz et al 2007). 
This trial concluded that adding misoprostol (600 μg/day) 
to standardized proton pump inhibitor treatment did not 
improve or change the rebleeding or mortality rates of 
patients with upper GI bleeding related to aspirin/NSAID 
use. In another study, patients with a history of upper GI 
bleeding who were infected with H. pylori and who were 
taking low-dose aspirin or other NSAIDs were screened 
(Chan et al 2001). It was found that among patients with 
H. pylori infection and a history of upper GI bleeding who 
were taking low-dose aspirin, the eradication of H. pylori 
was equivalent to treatment with omeprazole in preventing 
recurrent bleeding. Omeprazole turned out to be superior 
to the eradication of H. pylori in preventing recurrent 
bleeding in patients who are taking other NSAIDs. Sung 
and colleagues (1995) studied the efﬁ  cacy of antibacterial 
therapy without medication to suppress gastric acid for the 
treatment of patients with H. pylori infection and gastric 
ulcers unrelated to the use of nonsteroidal agents. Patients 
received one-week course of antibacterial agents (120 mg 
of bismuth subcitrate, 500 mg of tetracycline, and 400 mg 
of metronidazole, each given orally four times a day) or a 
four-week course of omeprazole (20 mg orally per day). 
As a result, in patients with H. pylori infection and gastric 
ulcers unrelated to the use of NSAIDs, one week of 
antibacterial therapy without acid suppression heals the 
ulcers as well as omeprazole and reduces the rate of their 
recurrence.
Despite the success rates of various antibiotic combina-
tions between 50%–75%, the antibiotic resistance and poor 
compliance signiﬁ  cantly affect the effectiveness of these 
strategies. Furthermore, antibiotic-based therapies are not 
suited for large-scale eradication in populations like middle 
age individuals in emergent societies whose life expectancy 
changes, with a concomitant increased gastric cancer risk 
(Michetti 2004).
Inﬂ  ammatory bowel diseases
Today, the IBD, which include Crohn’s disease and UC, 
affects 1 million people in the United States alone (Marx 
2007). In the thorough study by Pierik and colleagues (2006) 
the following common drugs in treatment of IBDs, UC, and 
Crohn’s disease were analyzed: sulfasalazine and mesalazine, 
azathioprine (AZA) and 6-mercaptopurine (6-MP), metho-
trexate (MTX), glucocorticosteroids, and inﬂ  iximab.
Various case reports suggest a relation between side 
effects like leukopenia and a mononucleosis-like syndrome 
and one of the slow acetylating genotypes in IBD patients 
treated with sulphasalazine (Ohtani et al 2003; Teshima 
et al 2003). Side effects are less common with mesalazine 
compared to sulphasalazine but there is still some concern 
about nephrotoxicity with long term use (Pierik et al 2006). 
The antiinﬂ  ammatory effect of MTX therapy on IBD is not 
clearly known and no studies are available at this time (Pierik 
et al 2006). Although glucocorticosteroids are an effective 
therapy choice in the initial treatment of most IBD cases, 
a retrospective population-based American study reported 
28% and 22% steroid dependency in Crohn’s disease and 
UC patients and 16% steroid resistance after one year of 
treatment (Faubion et al 2001). In addition, several studies 
report a high frequency of steroid resistance of Caucasian 
IBD patients and high surgical interventions (Munkholm et al 
1994; Reinisch et al 1995; Faubion et al 2001).
Nuclear factor kappa B (NF-κB) and p38 mitogen-
activated protein kinase pathways (MAPK) have been 
shown to be present in rheumatoid arthritis and inﬂ  am-
matory bowel disease lesions and are therefore interest-
ing targets for pharmacological intervention (Marok et al 
1996; Thiele et al 1999; Schett et al 2000; Waetzig et al 
2002). NF-κB constitutes a ubiquitously expressed family 
of inducible dimeric transcription factors that regulate 
the expression of many genes whose encoded products 
prominently affect immune functions and cell death Biologics: Targets & Therapy 2008:2(3) 360
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decisions (Karin et al 2004). Target genes of NF-κB can 
be categorized as inhibitors of apoptosis, promoters of 
cell proliferation and inﬂ  ammatory mediators (Karin and 
Delhase 2000). Studies show that aminosalicylates and 
corticosteroids, used to treat IBD, inhibit cytokine-induced 
activation of NF-κB. Sulfasalazine blocks activity of the 
IKK complex in intestinal epithelial cells, and mesalamine 
has been reported to have similar effects (Wahl et al 1998). 
Moreover, mesalamine can also inhibit phospohorylation of 
the p65 subunit of NF-κB, a post-translational modiﬁ  cation 
that is essential for its transcriptional activity (Egan et al 
1999). Corticosteroids have been shown to block NF-κB 
activation in a number of different mechanisms, including 
transcription upregulation of IκBα, an important endog-
enous inhibitor of NF-κB, and through competition for 
limiting pools of essential transcriptional co-activators, 
such as p300 (Auphan et al 1995). In addition to these 
drugs that can directly inhibit NF-κB activation, antibod-
ies against tumor necrosis factor-α can also limit NF-κB 
activity by neutralizing this cytokine, which is a potent 
activator of NF-κB. While all of these mechanisms have 
been studied in in vitro experiments, it is not established 
to what extent NF-κB inhibition is the precise molecular 
mechanism that underlies the beneﬁ  cial effects of any of 
these drugs in vivo. In terms of MAPK pathways, currently 
there is a controversy whether there is a signiﬁ  cant activa-
tion of MAPK pathways in experimental murine colitis or 
in human inﬂ  ammatory bowel disease. So far the results to 
assess if MAPK inhibitors might be beneﬁ  cial in inﬂ  am-
matory bowel disease have been inconsistent and several 
trials failed to demonstrate efﬁ  cacy (ten Hove et al 2002; 
Hollenbach et al 2004, 2005; Malamut et al 2006).
In addition to NF-κB and p38 MAPK, the peroxisome 
proliferator activated receptor-γ (PPARγ) is a nuclear recep-
tor controlling the expression of a large number of regulatory 
genes in lipid metabolism and insulin sensitisation, as well 
as in inﬂ  ammation and cell proliferation (Debril et al 2001; 
Fajas et al 2001). The role of this receptor in gut homeo-
stasis has been described in numerous articles and it has 
been linked with such conditions as IBD, Crohn’s disease, 
UC, colitis and ileitis (Sokolowska et al 2005; Slattery et al 
2005; Koh et al 2006; Sastre et al 2006). In the study by 
Ramakers and colleagues (2007), mice were gavaged with 
PPARγ agonists prior to colitis induction. Animals were 
treated with rosiglitazone and after 16 days impairment of 
colitis was observed. This positive outcome initiated further 
testing, this time in clinical trials. In the study by Lewis and 
colleagues (2001), the efﬁ  cacy of rosiglitazone was tested on 
15 patients with mild to moderately active UC. Thirteen of 
15 patients were receiving concomitant therapy with corti-
costeroids and/or immunomodulator medications. There was 
a decrease observed in disease with clinical and endoscopic 
remission (27% and 20%, respectively) or part response 
(27%) in eight patients. This study in IBD patients led to 
new clinical trials in IBD with these chemical compounds, 
and may lead to the development of safer PPAR-γ agonist 
with topical effects and targeting selectively the colon 
(Dubuquoy et al 2000).
Colon cancer
Colorectal cancer is the most common cancer in Western 
countries and the second leading cause of cancer-related 
deaths. Colorectal cancer is the second leading cause of 
cancer-related deaths in the United States, accounting 
for nearly 60,000 deaths each year (Jemal et al 2006). 
In addition, at least 100 million patients in the USA and 
Canada have recurrent long-term GI problems. According 
to the National Cancer Institute, cancer of the colon is the 
second leading cancer diagnosis among both women and 
men in United States. Sporadic lesions represent 75%–80% 
of all colorectal cancer, whereas 20%–25% are in younger 
individuals or in patients with a family history of cancer, 
suggesting a heritable susceptibility (Rodriguez-Moranta 
and Castells 2005). Although there have been recent 
advances in adjuvant therapy, there are no major break-
throughs in the treatment of colorectal cancers. Animal 
studies have provided important insights into the etiology 
of colon cancer, but there have been no major advances 
in the prevention of this disease. For instance, pancreatic 
cancer still contributes to high mortality rates since the 
average survival time after its detection is less than one 
year. The lack of treatment is due to no advances made in 
understanding the cause of this disease.
A recent in vitro study investigated a new drug for 
treatment of metastatic colorectal cancer, irinotecan 
(CPT-11) (Le et al 2006). The cytotoxic effect of the new 
drug was evaluated alone and in combination with mito-
mycin C (MMC) and hyperthermia on three colorectal 
cancer cell lines: CACO-2, HT-29, and DHD/K12/TRb 
(PROb). It was found that the combination of CPT-11 
and MMC had a large spectrum of cytotoxicity in in vitro 
models. This indicates that a clinical use of intraperito-
neal chemohyperthermia with MMC and CPT-11 to treat 
colorectal peritoneal carcinomatosis of colorectal origin 
was designed. However, further in vivo studies need to 
conﬁ  rm these ﬁ  ndings.Biologics: Targets & Therapy 2008:2(3) 361
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In vitro and in vivo studies tested the effect of combined 
therapy with demethylating agent 5-aza-2’-deoxycytidine 
(DAC) and irinotecan (CPT-11) on the human colon cancer 
cell line HCT-15 (Ishiguro et al 2006). It was postulated that 
DAC might increase the tumor sensitivity to chemotherapy 
through demethylation and restoration of gene expression. 
It was concluded that pretreatment with low-dose DAC may 
have the potential to be used as a “biosensitizer” of DNA-
damaging agents such as CPT-11 when the apoptotic pathway 
is inactivated as a result of aberrant promoter methylation 
in the cancer.
There are some studies indicating that regular use of 
NSAIDs may be associated with decreased colorectal 
cancer risk (Peleg et al 1994, 1996; Reeves et al 1996; 
Chan et al 2005). However, the studies did not take into 
consideration whether the lowering of the cancer incidence 
was due to tumors of the proximal or distal colon. In a 
study by Mahipal and colleagues (2006), the impact of 
NSAIDs on the proximal and distal colon was evaluated. 
The study found statistically not signiﬁ  cant association 
between either distal colon or rectal cancer and aspirin or 
nonaspirin NSAID use. Unfortunately, the use of NSAID 
drugs like aspirin, whether enteric- or nonenteric-coated, 
leads to side effects like GI bleeding (Kelly et al 1996; 
Rao 1997; Banoob et al 2002) and digestive complications 
(Lanas 2001; Sibilia et al 2003). A comprehensive review 
on aspirin-related GI side-effects and the mechanism by 
which aspirin causes GI damage was published by Hochain 
and colleagues (2000).
Although much has been learned about the incidence 
of colorectal cancer in patients who have IBD and its 
correlation with disease activity, duration, and anatomic 
location; almost no data are available regarding speciﬁ  c 
therapeutic considerations during adjuvant or palliative che-
motherapy for these patients with respect to their underlying 
disease (Goessling and Mayer 2006). Today the adjuvant 
therapy for colorectal cancer consists primarily of combi-
nations of 5-ﬂ  uorouracil/leucovorin (5-FU/LV) (with infu-
sional or bolus 5-FU) with oxaliplatin or oral capecitabine. 
In addition, bevacizumab, the angiogenesis inhibitor and 
cetuximab the epidermal growth factor receptor inhibitor 
are supplemented (de Gramont et al 2006). In depth results 
of Phase III trials of infusional 5-ﬂ  uorouracil/leucovorin 
and oxaliplatin (FOLFOX) as a new standard of care in the 
palliative and adjuvant treatment of colorectal cancer have 
been summarized in a review by Grothey and Goldberg 
(2004). In addition to already mentioned pharmacologic 
treatments, the nonpharmacologic ones are being widely 
tested as well and reported to modestly alter sporadic 
adenoma recurrence rates in randomized trials. These 
include calcium (Heaney 2006), folic acid (Larsson et al 
2006), and selenium (Gonzalez and Salas-Salvado 2006). 
Table 1 summarizes the above GI diseases and their treat-
ment limitations.
Limitations
Dyspepsia, nausea, vomiting, diarrhea, and constipation are 
just few of many side effects increasingly seen in patients 
taking GI drugs (Leong and Chan 2006). Mucosal ulceration 
that can manifest as GI hemorrhage, stricture, and perfora-
tion are examples.
In one study, 1.4 million people aged 66 years and older 
were examined for upper GI hemorrhage in British Colum-
bia and Ontario (Mamdani et al 2006). It was observed that 
patients treated with selective cyclooxygenase-2 (COX-2) 
inhibitors had increased upper GI hemorrhage. Although 
in a recent report by Lanas and Ferrandez (2006) we ﬁ  nd 
out that selective cyclooxygenase-2 (COX-2) inhibitors 
(coxibs) are safer to the GIT than traditional NSAIDs, 
they may increase the incidence of serious cardiovascular 
adverse events (CVEs). In addition, coxib therapy is more 
expensive than combination therapy using a nonselective 
NSAID and a proton-pump inhibitor (Hur et al 2006). 
Another study clearly states that NSAIDs produce symp-
toms of dyspepsia and peptic ulcer disease in up to 50% 
and up to 20%, respectively, of individuals taking them 
(Peura 2004).
Nonsteroidal antiinﬂ  ammatory drug toxicity in the upper 
GIT is the most common serious drug-induced toxicity 
reported to drug regulatory authorities. While differences 
exist between NSAIDs and aspirin, most studies have shown 
that advanced age, history of peptic ulcer disease, serious 
concomitant illnesses, and coprescription of NSAID/aspirin 
with anticoagulants and steroids are high risk factors. The 
use of potent antiulcer therapy, treatment of H. pylori infec-
tion and the development of COX-2 inhibitor will change 
the scenario of NSAID/aspirin-related GI toxicity in the next 
millennium (Sung et al 2000).
To sum up, many promising ﬁ  elds have already con-
tributed to a better understanding of some of the underlying 
mechanisms of GI diseases. By means of pharmacogenetics, 
molecular genetics, introduction of immune-modulators and 
monoclonal antibodies and other techniques great advances 
have been made in the management of the above diseases. 
However, a curative safe therapy does not yet exist. Due to 
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and an apparent transient, small reversal in the otherwise 
increasing pH gradient are factors which vastly limit and 
delay the already extensively explored research for initiating 
colon-speciﬁ  c drug release (Yang et al 2002).
The use of drugs is still an essential part of the physician’s 
armamentarium. However, given the evolving potential side-
effects information, physicians and patients should weigh the 
beneﬁ  ts and risks of these treatments. The drug use and drug 
coverage policies should be more restrictive; although limit-
ing access to drugs and their potential beneﬁ  ts may protect 
the population from adverse drug effects as well as the need 
to routinely reassess patients’ health.
Delivery of bacterial cells currently 
used for treating GI speciﬁ  c diseases
According to Doron and Gorbach (2006), a probiotic is a “live 
microbial food ingredients that, when ingested in sufﬁ  cient 
quantities, exerts health beneﬁ  ts on the consumer”. Lactic 
acid bacteria (LAB) are the organisms most commonly used 
as probiotics (Salminen et al 1998). Probiotics exert their 
Table 1 Various gastrointestinal diseases and their treatment limitations
Disease Proposed treatment Potential adverse 
symptoms/problems
References
Collagenous colitis Prednisolone
Boswellia serrata
Accumulation of lymphocytes 
in the colonic epithelium and 
connective tissue
Thickening of the subepithelial 
collagen table
Duncan et al 1997; Lazenby 
2005
Diarrhea Prednisolone
Omeprazole
Asprin
Bisphosphonates
Frequent watery, loose bowel 
movements
Damage to the mucosal lining
An inhibition of absorption
Spreux et al 1993; 
Chassany et al 2000; 
Fernandez-Banares et al 
2006
Microscopic colitis Bismuth subsalicylates
Budesonide
Prednisolone
Boswellia serrata
Cholestyramine
5-aminosalicylic acid
Profuse watery diarrhea
Higher incidence of immune 
diseases
Abdo and Beck 2003; Chang 
et al 2005; Chande et al 2006
Gastritis Omeprazole
Aspirin
Mistoprostol
Tetracycline
Metronidazole
Antibiotic resistance
Gastric ulcers
Gastrointestinal bleeding
Recurrent abdominal pain
Increased gastric cancer risk
Sung et al 1995; Chan et al 
2001; Michetti 2004; Yilmaz 
et al 2007
Inﬂ  ammatory bowel disease Sulfasalazine
Mesalazine
Azathioprine
6-mercaptopurine
Methotrexate
Glucocorticosteroids
Inﬂ  iximab
Leukopenia
Mononucleosis-like syndrome
Nephrotoxicity
Steroid resistance which leads 
to surgical interventions
Munkholm et al 1994; 
Reinisch et al 1995; Faubion 
et al 2001; Ohtani et al 2003; 
Teshima et al 2003; Pierik 
et al 2006
Colon cancer Irinotecan (CPT-11)
Mitomycin C (MMC)
5-aza-2’-deoxycytidine (DAC) 
irinotecan (CPT-11)
NSAID
5-ﬂ  uorouracil/ leucovorin 
(5-FU/LV)
Oxaliplatin Capecitabine
Toxicity
Gastrointestinal bleeding
Digestive complications
Temporary effect on bone 
marrow
Hair loss
Anemia
Overall fatigue
May increase cardiovascular 
adverse events
Lowered resistance to 
infections
No data about speciﬁ  city 
of treatments
Kelly et al 1996; Rao 1997; 
Banoob et al 2002; Sibilia 
et al 2003; Grothey and 
Goldberg 2004; de Gramont 
et al 2006; Ishiguro et al 
2006; Lanas and Ferrandez 
2006; Le et al 2006; Mahipal 
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beneﬁ  ts through several mechanisms; they prevent coloniza-
tion, cellular adhesion and invasion by pathogenic organisms, 
they have direct antimicrobial activity and they modulate the 
host immune response. The strongest evidence for the clinical 
effectiveness of probiotics has been in their use for the preven-
tion of symptoms of lactose intolerance, treatment of acute 
diarrhea, attenuation of antibiotic-associated GI side effects 
and the prevention and treatment of allergy manifestations.
An interesting study was performed by Galdeano and 
Perdignon (2004) with probiotic strains and their adherence 
patterns in the gut and in mucosal immune stimulation. 
Lactobacillus casei interaction with the gut was observed 
using transmission electron microscopy (TEM). The study 
demonstrated that only antigenic particles interact with the 
immune cells and their fast clearance from the gut agrees 
with those described for the particulate antigens.
The above study proved that regular ingestion of probiotics 
does not interfere with the host gut microﬂ  ora but does exert 
health benefits on the consumer. In another study with 
guinea pigs the intestinal motility changes were monitored 
by testing 8 bacterial strains belonging to Biﬁ  dobacterium, 
Lactobacillus, and Streptococcus genera within the probi-
otic preparation VSL#3 (VSL Pharmaceuticals Inc., Fort 
Lauderdale, MD, USA; VSL Pharmaceuticals 2007). The 
outcome revealed that the proximal colon relaxation activity 
showed by the probiotic bacteria could be one of the possible 
mechanisms of action by which probiotics exert their positive 
effects in regulating intestinal motility (Massi et al 2006).
Although, probiotic therapy modulates the composition 
of the intestinal ﬂ  ora and is believed to inhibit the inﬂ  am-
matory response, the metabolic activity of some intestinal 
microorganisms inhabiting the gut may lead to the production 
of harmful substances. These substances could be metaboli-
cally undesirable (eg, d-lactic acid for the newborn) or might 
lead to potentially carcinogenic substances such as N-nitroso 
compounds (Goldin 1986). Therefore a thorough assessment 
of speciﬁ  c strains as well as doses seems to be essential.
The following section summarizes numerous studies 
which tested probiotic bacterial strains in treatment of various 
diseases.
Various GI diseases treated 
with biotherapeutics
Rotavirus diarrhea, acute diarrhea, 
antibiotic-associated diarrhea
There has been a great amount of research done in the ﬁ  eld 
of probiotics and their effect on diarrhea. Rotavirus diarrhea 
is the major cause of infantile gastroenteritis worldwide and 
the infection is associated with approximately 600,000 deaths 
every year, predominantly in developing countries. A study 
by Chapoy (1985) and Cetina-Sauri and Sierra-Basto (1994) 
focused on treatment of acute diarrhea using Saccharomyces 
boulardii. A randomized, double-blind, placebo controlled 
clinical trial was conducted by Salazar-Lindo and colleagues 
(2004) to screen Lactobacillus casei strain GG in the treat-
ment of infants with acute watery diarrhea. A meta-analysis 
was performed by Huang and colleagues (2002) to validate 
the efﬁ  cacy of probiotic use in acute diarrhea in children 
where a co-administration of probiotics with standard rehy-
dration therapy reduced the duration of acute diarrhea by 
approximately one day. Another study on 55 infants aged 
5–24 months, was performed by Saavedra and colleagues 
(1994) to explore the prevention of diarrhea in hospitalized 
infants using Biﬁ  dobacterium lactis (BB12) and Streptococ-
cus thermophilus. Lactobacillus GG was used in prevention 
of nosocomial diarrhea in infants in the study by Szajewska 
and colleagues (2001) which concluded that a prophylactic 
use of Lactobacillus GG signiﬁ  cantly reduced the risk of 
nosocomial diarrhea in infants, particularly nosocomial 
rotavirus gastroenteritis. Lactobacillus reuteri and B. lactis 
were compared in a double-blind, placebo-controlled, ran-
domized trial by Weizman and colleagues (2005) to screen 
for preventative properties of daycare illness with positive 
results suggesting that children supplemented with formulas 
with L. reuteri or B. lactis had fewer and shorter episodes of 
diarrhea, with no effect on respiratory illnesses. The effects of 
long-term consumption of a fermented infant formula (with 
Biﬁ  dobacterium breve c50 and Streptococcus thermophilus 
065 was evaluated on acute diarrhea in healthy infants with 
the outcome that a fermented formula may reduce the severity 
of acute diarrhea among healthy young infants which may 
be linked to the biﬁ  dogenic effects of fermentation products 
and their interactions with the intestinal immune system 
(Thibault et al 2004).
A randomized placebo-controlled double-blind study with 
220 hospitalized children was conducted to assess the efﬁ  cacy 
of Lactobacillus GG vs. breast-feeding in the prevention of 
rotavirus nosocomial infection concluding that breast feeding 
was more beneﬁ  cial (Mastretta et al 2002). Saccharomyces 
boulardii and placebo were used in an antibiotic-associated 
diarrhea prevention randomized-controlled trial by Kotowska 
and colleagues (2005) with 269 children reaching positive 
evidence that S. boulardii effectively reduces the risk of 
antibiotic-associated diarrhea in children because only 
8% had presence of diarrhea. A meta-study screening Biologics: Targets & Therapy 2008:2(3) 364
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the efﬁ  cacy of probiotics in prevention and treatment of 
diarrhea associated with the use of antibiotics was done 
using 9 randomized double-blind placebo-controlled trials 
with children with 4 yeast, 4 lactobacilli and 3 combination 
of bacteria by D’Souza and colleagues (2002) concluded 
that the evidence of probiotics beneﬁ  cial role still needs 
to be proven by designing a larger scale study. Another 
randomized, placebo-controlled trial was conducted using 
the probiotic Lactobacillus rhamnosus strain GG (LGG) to 
see if the addition of LGG to standard therapy prolonged 
remission in children with Crohn’s disease by Bousvaros and 
colleagues (2005) with 75 children which resulted in median 
time to relapse of 9.8 months for LGG group and 11 months 
for placebo group. In this study the differences were not 
statistically signiﬁ  cant but no beneﬁ  t of probiotics was 
apparent (Bousvaros et al 2005). A study using L. acidophilus 
and B. infantis was conducted on 367 preterm infants in 
treatment of necrotizing enterocolitis by Lin and colleagues 
(2005) and resulted in death of 7 vs 20 a significantly 
lower in the study when compared with the control group. 
O’Mahony and colleagues (2005) studied Lactobacillus 
salivarius UCC4331 and Biﬁ  dobacterium infantis 35624 in 
77 adult IBS patients to compare the response of symptoms 
and cytokine ratios after ingestion of probiotic preparations 
resulting in B. infantis reducing pain, bloating and suggesting 
an immune-modulating role for this organism.
Gastric ulcers caused by Helicobacter 
pylori
In a double-blind, randomized, controlled clinical trial, 
326 H. pylori-infected school children from a low 
social economic area of Santiago, Chile were treated 
with both live and heat-killed strains of Lactobacillus 
johnsonii, Lactobacillus paracasei or vehicle once daily 
for 4 weeks. A C13-urea breath test demonstrated a 
signiﬁ  cant fall in H. pylori colonization in children receiv-
ing live L. johnsonii, but not the other groups. Once again, 
this study implies a probiotic species speciﬁ  city for the 
therapeutic effect (Cruchet et al 2003). Sheu and colleagues 
(2006) have screened the impact of Lactobacillus- and 
Biﬁ  dobacterim-containing yogurt on H. pylori in 138 patients. 
The suppression rate was improved in eradication rate 
by quadruple therapy of residual H. pylori after failed 
triple therapy. Another study focused on H. pylori-infected 
children by administration of a probiotic, Lactobacillus 
acidophilus and comparing its efﬁ  cacy with a synbiotic, 
Saccharomyces boulardii plus inulin (SbI) (Gotteland et al 
2005). The study concluded that S. boulardii may serve as 
an agent that ﬁ  ghts H. pylori in colonized individuals. In the 
presence of clarithomycin-resistant H. pylori, eradication is 
signiﬁ  cantly attenuated. An interesting randomized study 
was run on 85 H. pylori patients undergoing eradication with 
triple therapy using the following probiotics: Lactobacillus 
casei subspecies rhamnosus, Saccharomyces boulardii, 
Lactobacillus acidophilus plus Biﬁ  dobacterium lactis or pla-
cebo (Cremonini et al 2002). As a result, all the groups given 
probiotics performed better than placebo group but failed to 
be superior to antibiotic therapy. Ushiyama and colleagues 
(2003) demonstrated that Lactobacillus gasseri inhibited 
both the in vitro growth of clarithomycin-resistant H. pylori 
and the release of IL-8 from epithelial cells. In addition, in an 
in vivo mouse model, H. pylori colonization was signiﬁ  cantly 
decreased by Lactobacillus gasseri. Another inhibitory effect 
was demonstrated by Chatterjee and colleagues (2003) in a 
study with Lactobacillus acidophilus on H. pylori growth. In 
addition to studies screening the efﬁ  cacy of probiotic strains 
in treatment of H. pylori infection, another study conﬁ  rmed a 
positive impact that Lactobacillus GG has on GI side-effects 
caused by H. pylori antibiotic therapy (Armuzzi et al 2001). 
The above studies support the complementary effect of 
probiotics in the management of H. pylori infection.
The role of H. pylori in the management of nonulcer 
dyspepsia produced numerous H. pylori eradication 
regimens, but despite many studies no perfect therapy has 
been identiﬁ  ed so far. The American College of Gastroen-
terology has published a set of guidelines for the treatment 
and prevention of NSAID-induced ulcers (Lanza 1998). 
This contains a well-motivated, practical approach to the 
problem of NSAID ulceration; emphasizes the “risk proﬁ  le” 
approach to selection of patients for prophylaxis; and presents 
compelling arguments against the routine use of H2-receptor 
antagonists for NSAID prophylaxis. The role of H. pylori is 
also addressed. Screening for H. pylori infection in NSAID 
users is not currently recommended, but patients with past 
or present ulceration who need NSAID therapy should also 
receive eradication therapy (Louw and Marks 1999). Lau 
and colleagues () questioned the conventional wisdom that 
surgery is indicated for peptic ulcer rebleeding.
Inﬂ  ammatory bowel disease
Inﬂ  ammatory bowel disease (IBD) is a chronic disease of the 
digestive tract, and usually refers to two related conditions, 
namely UC and Crohn’s disease, characterized by chronic 
and spontaneously relapsing inﬂ  ammation. Although the 
etiology of IBD is still insufficient, there is increasing 
experimental evidence to support a role for luminal bacteria Biologics: Targets & Therapy 2008:2(3) 365
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in the initiation and progression of these intestinal conditions; 
probably related to an imbalance in the intestinal microﬂ  ora, 
relative predominance of aggressive bacteria and insufﬁ  cient 
amount of protective species (Fiocchi 1998; Shanahan 
2000). The current hypothesis in the pathogenesis of the 
chronic idiopathic IBD, Crohn’s disease, and UC, suggests 
that these are caused by an overly aggressive cell-mediated 
immune response to luminal commensal bacteria in geneti-
cally susceptible hosts (Sartor 2004; Shanahan 2005). In 
addition, IBDs are multifactorial processes and clinical and 
animal studies indicate that emotional stress may contribute 
to the onset and progress of these diseases. On the other 
hand, enhanced free radical production in mucosal cells has 
been also implicated in the pathogenesis of IBD (Colon et al 
2004). This disease was described for the ﬁ  rst time in 1952 
(Crohn et al 1952) and today, it has been estimated that at 
least 3.5 million Americans visit their physicians each year 
for IBD which accounts for 25% of all patients seen in 
gastroenterologists’ practice, with 15,000–30,000 new cases 
being diagnosed each year (Everhart and Renault 1991). 
Crohn’s disease is most common in the developed countries 
of Europe, Scandinavia, and the US and generally is thought 
to be more common in whites (Sandler and Golden 1986).
In the systematic review by Inadomi and colleagues 
(2003) it was estimated that £45.6 million was spent annually 
in the UK for IBD care, translating into approximately £90 
annually in costs per patient. On the other hand, the annual 
mean direct costs of caring for IBS patients in Canada were 
estimated to be US$260 (Bentkover et al 1999).
A primary goal in treating CD is to control GIT inﬂ  am-
mation. Currently, the treatment of this disease is based on its 
degree of inﬂ  ammation and consists of dietary adjustments, 
surgery and various medications including antiinﬂ  ammatory 
drugs, steroids, immunosuppressants, antibiotics, antitumor 
necrosis factor (anti-TNF) drugs, antidiarrheals and other 
symptom suppressing drugs. However, an ideal treatment 
is yet to be found (Caprilli et al 2002; Gruner et al 2002). 
As in other inﬂ  ammatory processes, IBD is characterized 
by an upregulation in the synthesis and release of different 
pro-inﬂ  ammatory cytokines, including reactive oxygen and 
nitrogen metabolites, eicosanoids, platelet-activating factor, 
and cytokines (Stenson 1994). All of these mediators contrib-
ute to the pathogenic cascade that initiates and perpetuates the 
inﬂ  ammatory response of the gut. As a consequence, and until 
its etiology has been completely elucidated, the best strategy 
to effectively down-regulate intestinal inﬂ  ammation is to 
interfere with multiple stages of the inﬂ  ammatory cascade, 
preferably with a single drug treatment (Galvez et al 2001).
Serological markers such as anti-Saccharomyces 
cerevisiae antibodies (ASCA) and atypical perinuclear 
antineutrophilic cytoplasmic antibody (atypical pANCA) 
have proven useful in the diagnosis and differentiation of 
Crohn’s disease and UC (Jaskowski et al 2006).
Biologic and other novel therapies targeted to speciﬁ  c 
pathogenic processes offer the potential for improved 
treatment outcomes in patients with CD and alteration 
of the course of the disease (Sandborn 2001). A possible 
therapeutic approach in IBD therapy is the administration 
to these patients of probiotic microorganisms, deﬁ  ned as 
viable nutritional agents conferring beneﬁ  ts to the health of 
the human host (Peran et al 2005).
This complex interplay of genetic, microbial and 
environmental factors culminates in a sustained activation 
of the mucosal immune and nonimmune response, probably 
facilitated by defects in the intestinal epithelial barrier and 
mucosal immune system, resulting in active inﬂ  ammation 
and tissue destruction. Under normal situations, the intestinal 
mucosa is in a state of ‘controlled’ inﬂ  ammation regulated 
by a delicate balance of proinﬂ  ammatory (TNF-α, interferon 
[IFN]-γ, interleukin [IL]-1, IL-6, IL-12) and antiinﬂ  amma-
tory cytokines (IL-4, IL-10, IL-11). The mucosal immune 
system is the central effector of intestinal inﬂ  ammation and 
injury, with cytokines playing a central role in modulating 
inﬂ  ammation (Ardizzone and Porro 2005). For inﬂ  ammatory 
bowel diseases (IBD) the most important cytokines identiﬁ  ed 
are IL-1, IL-2, IL-6, IL-8, IFN-γ, and TNF-α (van Hogezand 
and Verspaget 1996). Cytokines may, therefore, be a logical 
target for IBD therapy using speciﬁ  c cytokine inhibitors.
At present, the biological therapies that are being used in 
clinical practice or investigated for the treatment of IBD are 
predominantly proteins, usually delivered intravenously or 
subcutaneously. The therapies used include: 1. TNF-α inhibi-
tors: inﬂ  iximab, CDP 571, etanercept, onercept, CNI-1493, 
and thalidomide. 2. Inhibitors of lymphocyte trafﬁ  cking: 
natalizumab, LPD-02 and ICAM-1. 3. Inhibitors of Th1 
polarization: monoclonal antibodies for IL-12, IFN-γ and 
anti-IFN-γ. 4. Immunoregulatory cytokines: IL-10 and 
IL-11. 5. Inhibitors of NF-κB. 6. Growth factors: epidermal 
growth factor (EGF) and keratinocyte growth factor (KGF) 
(Kurtovic and Segal 2004). Therefore, targeted molecules 
can be speciﬁ  cally eliminated in their expression directly 
on the transcriptional level. Interesting therapeutic trials are 
expected against ICAM-1 and pro-inﬂ  ammatory signaling 
molecules (ie, NF-κB). The future development of immune 
therapies in IBD therefore holds great promises for better 
treatment modalities of IBD but will also open important Biologics: Targets & Therapy 2008:2(3) 366
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new insights into a further understanding of inﬂ  ammation 
pathophysiology (Schreiber 1998).
Current treatment of IBD is rather effective though it is 
only working in symptomatic fashion. Most recombinant 
"biologicals" have not been an overwhelming success. 
Inﬂ  iximab has shown clinically relevant efﬁ  cacy and is used 
in patients not responding to the standards. Alternatives such 
as modulating the bacterial-epithelial interaction, tightening 
of the mucosal barrier and maybe even immunostimulation 
should be studied since most recent ﬁ  nding on etiology and 
pathophysiology point to a disturbed barrier with consequent 
abnormal bacterial epithelial interaction as the main problem 
in the IBD syndrome (Scholmerich 2006).
There is currently a growing appreciation for the role 
of the enteric ﬂ  ora in health and disease. In the past years 
overwhelming evidence has accumulated for the role of 
commensal gut bacteria in the IBD, Crohn's disease, and UC. 
Both entities are mainly located in areas with high bacterial 
concentrations (Bohm and Kruis 2006).
In the last decade there were ﬁ  ve main clinical trials that 
examined various probiotics, namely species of Lactobacillus, 
in the treatment of IBD (Halpern et al 1996; Nobaek et al 
2000; O’Sullivan and O’Morain 2000; Niedzielin et al 2001; 
Sen et al 2002). In the past years, many reviews have been 
written about IBS as well as the role of microﬂ  ora in IBS 
(Madden and Hunter 2002; Floch 2003). In a randomized 
controlled clinical trial, Kim and colleagues (2003) examined 
the effects of a probiotic formulation containing eight 
different probiotic species, VSL#3 supplementing 450 billion 
lyophilized bacteria/day (VSL Pharmaceuticals Inc.), on GI 
transit and symptoms of patients with diarrhea predominantly 
IBS. After 10 weeks of treatment, there was no signiﬁ  cant 
difference in mean GI transit measurements, bowel function 
scores or satisfactory global symptom relief between the two 
treatment groups. However, VSL#3 appears to be a promis-
ing agent in IBS as it signiﬁ  cantly reduced the abdominal 
bloating (Kim et al 2003).
The mechanism of action of probiotics in IBS remains 
still poorly understood due to changes and complexity in fer-
mentation products. Another study screened for lactobacilli, 
biﬁ  dobacteria, Streptococcus thermophilus, enterococci, 
coliforms, Bacteroides and Clostridium perfringens changes 
in the fecal composition of 10 patients with diarrhea-pre-
dominant IBS after administration of VSL#3 probitocs 
with positive results yielding no signiﬁ  cant alterations in 
indigenous ﬂ  ora (Brigidi et al 2001). In a similar open-label 
study, Bazzocchi and colleagues (2002) made use of the 
following hypothesis: “characteristics of the luminal milieu, 
the relationship, the balance between luminal prokaryotic 
cells and mucosal eukaryotic cells and the consequent 
immunological and humoral local and systemic responses 
take part in the pathophysiology of several diseases and, 
consequently bacteriotherapy can play a relevant role in 
the treatment and prevention of IBS and more in general, 
of the intestinal functional disorders”. He demonstrated 
that VSL#3 probiotic induced changes in the composi-
tion of the colonic microﬂ  ora together with improvement 
in colonic dysmotility and in visceral perception. On the 
other hand, in a double-blind, placebo-controlled, cross-
over, four-week trial of Lactobacillus plantarum 299V in 
12 previously untreated patients the probiotic did not alter 
colonic fermentation or improve symptoms in comparison 
with placebo (Sen et al 2002). An interesting study designed 
to conﬁ  rm the efﬁ  cacy of the probiotic bacteria B. infantis in 
a large-scale, multicenter, clinical trial of women with IBS 
as well as to determine the optimal dosage of probiotic for 
administration in a freeze-dried, encapsulated formulation 
was performed in UK (Whorwell et al 2006). A dose of 
1 × 10(8) cfu was the most stable, convenient and amenable 
to widespread use in IBS and that B. infantis relieved many 
of the IBS symptoms. Further studies evaluated the effect 
of probiotics Bacillus subtilis, Streptococcus faecium in 
a form of Medilac DS on GI symptoms and intestinal gas 
volume changes in forty patients with IBS (Kim et al 2006). 
After 4-week treatment, it was found that both probiotics 
are safe and useful agents in patients with IBS. The efﬁ  -
cacy of Lactobacillus GG was screened in the randomized, 
double-blinded, placebo-controlled study with 50 children 
for 6 weeks suffering from IBS (Bausserman and Michail 
2005). Although Lactobacillus GG turned out not to be 
superior to placebo in the treatment of abdominal pain in 
children with IBS it still may be promising in relieving such 
symptoms as perceived abdominal distention. The above 
studies present promising options in treatment of IBS as 
we gain more insightful information about the disease itself 
as well as variety of available probiotics with beneﬁ  cial 
properties. However, what needs to be emphasized is that 
these summarized results support the concept of speciﬁ  c 
probiotic strains being more effective that others across 
varied disease states.
Collagenous colitis
Collagenous colitis is a chronic inflammatory bowel 
disease that affects the colon (Wildt et al 2006a). It is also 
considered to be a cause of chronic diarrhea. Collagenous 
and lymphocytic colitis have been recognized as chronic Biologics: Targets & Therapy 2008:2(3) 367
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intestinal inﬂ  ammatory disorders causing watery diarrhea, 
which have been recognized in the past three to two decades, 
respectively. In a double-blind placebo-controlled study 
supervised by Wildt and colleagues (2006b) the effectiveness 
of probiotic treatment, namely: Lactobacillus acidophilus and 
Biﬁ  dobacterium animalis subsp. lactis has been screened in 
patients with collagenous colitis. The study concluded that 
probiotic treatment may potentially inﬂ  uence the disease 
course of collagenous colitis. In another trial, the therapeutic 
clinical beneﬁ  t was found of probiotic E. coli strain Nissle 
1917 (EcN) in patients with collagenous colitis (Tromm 
et al 2004).
Intestinal diseases caused by Escherichia 
coli
There are ﬁ  ve types of E. coli, enterotoxigenic, enteropatho-
genic, enteroadherent, enteroinvasive, and enterohemorrhagic 
E. coli, which are responsible for as much as 25% of all 
diarrheal diseases in developing countries. They tend to be 
transmitted via contaminated foods, particularly weaning 
foods, and water (Niyogi et al 1994). In an in vitro study, 
the effect of probiotic Lactobacillus casei GG (LGG) was 
tested to ﬁ  nd out that it has the effect of reducing the rate 
of E. coli C25 (E. coli C25) translocation. The study was 
performed using an in vitro cell-culture model with human 
colonic carcinoma (Caco-2) enterocytes. It was concluded 
that the probiotic bacterium LGG inhibits bacterial translo-
cation of E. coli C25 in a dose-dependent manner in an in 
vitro cell-culture model (Mattar et al 2001). In the study by 
Akil and colleagues (2006) with 24 children a commercial 
capsule or powder containing S. boulardii was administered 
once a day for 5 days to screen for the number of E. coli 
colonies in the colon. It was found that S. boulardii may 
be effective in reducing the number of E. coli colonies in 
stool which may lead to preventative treatment of urinary 
tract infections.
Colorectal cancer
Colorectal cancer, whether sporadic or hereditary, is 
caused by a defined set of molecular events (Tejpar 
and Van Cutsem 2002). Germline mutations in tumor-
suppressor adenomatous polyposis coli (APC) genes and 
DNA mismatch repair (MMR) genes lead to the recognized 
familial adenomatous polyposis (FAP)-related colorectal 
cancer and the hereditary non-polyposis colorectal cancer 
(HNPCC), respectively (Sandborn 2001). Bacterial ﬂ  ora 
keeps the normal colon mucosa in a continuous state of 
low-grade inﬂ  ammation, stimulating release of various 
pro-inﬂ  ammatory cytokines by the immune cells (Rhodes 
and Campbell 2002).
Anastomotic leakage of colonic and rectal anastomoses 
is a major complication after an intraperitoneal large-bowel 
anastomosis in patients with colorectal malignancy and 
after large intestine surgery. It is associated with a 6%–22% 
mortality rate. Many factors inﬂ  uence the healing of colon 
anastomoses. Flavonoids have been recognized for centuries 
as physiologically active constituents that are used to treat 
human diseases (Inan et al 2006).
Anal sphincter function is increasingly preserved 
following rectal excision for cancer and provides a better 
quality of life for patients than does a permanent colostomy. 
However, anastomotic complications may cause considerable 
morbidity and mortality (Dehni et al 1998).
The use of probiotics in prevention and cancer treat-
ment has been undergoing a recent evaluation in a number 
of studies. Although we should not expect miraculous 
outcomes in cancer treatment following probiotics admin-
istration, their immunomodulatory properties have been 
tested and need to be brought to publics’ attention. In the 
study by McIntosh and colleagues (1999) Lactobacillus 
acidophilus (Delvo Pro LA-1), Lactobacillus rhamnosus 
(GG), Bifidobacterium animalis (CSCC1941), and 
Streptococcus thermophilus (DD145) strains were exam-
ined for their inﬂ  uence on 1,2-dimethylhydrazine (DMH)-
induced intestinal tumors in 100 male Sprague-Dawley rats 
when added as freeze-dried bacteria. This study concluded 
that the strain of L. acidophilus supplied as freeze-dried 
bacteria in the diet was protective because it signiﬁ  cantly 
inhibited tumors within the rat colon. There is a substantial 
amount of studies done by Perdignon dealing with anti-
inﬂ  ammatory properties of probiotic bacteria. For instance, 
the probiotic bacterium Lactobacillus casei was screened 
for its inﬂ  uence on the expression of receptors involved in 
the innate immune response in colorectal cancer BALB/c 
model mice (Galdeano and Perdigon 2006). Further, a com-
plex nature of keﬁ  r was studied in BALB/c mice. Keﬁ  r is 
fermented milk produced by the action of lactic acid bacteria, 
yeasts and acetic acid bacteria, trapped in a complex matrix 
of polysaccharides and proteins. In addition, it is an excel-
lent source of proteins and calcium (Vinderola et al 2005). 
A conclusion was drawn that since different components of 
keﬁ  r have an in vivo role as oral biotherapeutic substances 
capable of stimulating immune cells of the innate immune 
system they are able to downregulate the Th2 immune 
phenotype or to promote cell-mediated immune responses 
against tumors and also against intracellular pathogenic Biologics: Targets & Therapy 2008:2(3) 368
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infections (Vinderola et al 2006). Another keﬁ  r-related study 
was done by Vinderola and colleagues (2005) which was 
the ﬁ  rst in vivo study to determine the immunomodulating 
capacity of keﬁ  r on the intestinal mucosal immune response 
in mice of viable or heat-inactivated bacteria at different 
doses. The adjuvant immunomodulatory effect of keﬁ  r 
was tested in rats, young and old (Thoreux and Schmucker 
2001). An enhanced in vitro antibody secretion by cultured 
lymphocytes isolated from the Peyer’s patches and the 
intestinal lamina propria were found only in young rats 
indicating that the administration of keﬁ  r to young rats has 
a beneﬁ  cial effect on intestinal mucosal immune response 
against cholera toxin.
Probiotics are useful in a variety of diarrheal diseases 
and may be useful in inﬂ  ammatory and allergic disorders. 
Table 2 summarizes the above described diseases and lists 
Table 2 Various pathological conditions treated with viable microorganisms (bacteria or yeasts) – probiotics
Disease Biotherapeutics 
used
Live bacterial 
cell optimal dose
Mode of delivery Potential site 
of action
References
Rotavirus diarrhea Lactobacillus GG
Lactobacillus reuteri
Lactobacillus acidophilus
Lactobacillus bulgaricus
Biﬁ  dobacterium biﬁ  dum
Streptococcus 
thermophilus
Saccharomyces boulardi
Lactobacillus casei
Biﬁ  dobacterum bulgaris
∼1010/d
∼109/d
∼1010/d
∼108/ml
∼1010/d
500 mg/d
500 mg/d
∼1010/d
∼1010/d
Capsules
Foods
Small and large 
intestines
Saavedra et al 1994; 
Szajewska et al 2001; 
D’Souza et al 2002; 
Huang et al 2002; 
Mastretta et al 2002; 
Salazar-Lindo et al 2004; 
Thibault et al 2004; 
Guandalini, 2006
Antibiotic associated 
diarrhea
Saccharomyces boulardi
Lactobacillus GG
500 mg/d
∼1010/d
Capsules
Foods
Small and large 
intestines
D’Souza et al 2002; 
Kotowska et al 2005
Radiation induced diarrhea VSL#3 (Lactobacillus 
casei, Lactobacillus 
plantarum, Lactobacillus 
acidophilus, Lactobacillus 
delbruekii ssp. bul-
garicus, Biﬁ  dobacterium 
longum, Biﬁ  dobacterium 
breve, Biﬁ  dobacterium 
infantis and Streptococ-
cus thermophilus)
4.5 × 109/2 capsules Capsules Small and large 
intestines
Delia et al 2002
Helicobacter pylori 
colonization/gastric ulcers
Lactobacillus johnsonni
Saccharomyces boulardi
Lactobacillus acidophilus
Lactobacillus gasseri
∼1010/d
500 mg/d
∼1010/d
∼108/d
Capsules Stomach, 
duodenum, 
small and large 
intestines
Cruchet et al 2003; 
Chatterjee et al 2003; 
Ushiyama et al 2003; 
Gotteland et al 2005; 
Sheu et al 2006
Inﬂ  ammatory bowel disease 
(IBD)
Escherichia coli Nissle
Saccharomyces boulardi
VSL#3
Lactobacillus GG
500 mg/d
∼1010/d
Capsules Small intestines Bousvaros et al 2005
Ulcerative Colitis Escherichia coli Nissle Capsules Small and large 
intestines
Halpern et al 1996; 
Langman and Allan 1999; 
Rembacken et al 1999
Irritable bowel syndrome Lactobacillus plantarii
Biﬁ  dobacterium infantis
∼1010/d
∼1010/d
Capsules Small and large 
intestines
Halpern et al 1996; 
O’Sullivan and O’Morain, 
2000; Nobaek et al 
2000; Brigidi et al 2001; 
Niedzielin et al 2001; 
Bazzocchi et al 2002; Sen 
et al 2002; O’Mahony 
et al 2005
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biotherapeutics used in their treatment, their dose, mode of 
delivery and potential site of action. In Table 3, a proposed 
mechanism of action is described along with marketed 
probiotic-containing products. It is important to note that 
the effects are strain- and dose-speciﬁ  c and therefore more 
clinical studies are needed to be designed screening each 
strain and disorder. Other problems that probiotic produc-
tion may encounter include: oxygen stress due to agitation 
during pH control, oxygen and pressure stresses during 
centrifugation or ﬁ  ltration, membrane damages during 
freeze-drying due to freezing itself and due to the drying 
step. In addition, such situations like production of inhibi-
tory compounds by starter cultures, heating–pasteurization, 
freezing, food additives (salt, spices, ﬂ  avors) and drying 
could further alter viability of probiotic species. However, 
probiotics appear to be safe, as it was shown in treatment 
with infants.
Microencapsulated live oral 
biotherapeutics, their potential 
and limitations
It was Lim and Sun (1980) who invented alginate-poly-
L-lysine-alginate (APA) microcapsule in 1980 and ever 
since microencapsulation has been proven to be an effective 
strategy for cell implantation and cell-based gene therapy 
for the treatment of diabetes, metabolic or neurologic, 
disorders, and cancer (Ross et al 2000; Sambanis 2003; 
Basta et al 2004; Luca et al 2005). As it was noted before, 
to obtain an efficient colon targeting biotherapeutics, 
the delivered materials need to be protected from the GI 
Table 2 (Continued)
Disease Biotherapeutics 
used
Live bacterial 
cell optimal dose
Mode of delivery Potential site 
of action
References
Collagenous colitis Lactobacillus acidophilus
Biﬁ  dobacterium animalis 
subsp. Lactis
∼1010/d
∼1010/d
Capsules
Injections
Large intestines Wildt et al 2006b
Colorectal cancer
 
Lactobacillus acidophilus
Lactobacillus rhamnosus
Biﬁ  dobacterium animalis
Streptococcus 
thermophilus
Lactobacillus casei
Capsules
Milk
Keﬁ  r
Large intestines McIntosh et al 1999; 
Thoreux and Schmucker 
2001;   Vinderola et al 
2005, 2006; Galdeano 
and Perdigon 2006
Table 3 Biotherapeutics, gastroenteric pathogens and their proposed mechanism of action and current marketed biotherapeutics 
products
Marketed probiotic products Probiotic content Disease causing microorganisms and their proposed mec
Culturelle Lactobacillus GG, Lactobacillus 
rhamnosis
Clostridium difﬁ  cile
Campylobacter jejuni
Helicobacter pylori
Rotavirus – leading etiologic 
agents of nosocomial infections 
among children
Atopic disease – eczema, 
asthma and rhinoconjunctivitis
Salmonella
Campylobacter
Escherichia coli
Staphylococcus aureus
Shigella spp.
Yersinia enterocolitica
–   Produce antimicrobial substances 
with activity against the homologous 
strain
–   Produce microbicidal substances 
with effect against gastric and 
intestinal pathogens and other 
microbes
–   Compete for cell surface and mucin 
binding sites
–   Inhibit or decrease translocation of 
bacteria from the gut to the liver
– Bind mutagens by intestinal bacteria
–   Reduce enzymes beta-glucoronidase 
and beta-glucosidase
– Deconjugate bile acids
– Enhance immune system of the host
– Stimulate intestinal mucin secretion
VSL (VSL#3) Lactobacillus casei, 
Lactobacillus plantarum, 
Lactobacillus acidophilus, 
Lactobacillus delbruekii ssp. 
bulgaricus, Biﬁ  dobacterium 
longum, Biﬁ  dobacterium breve, 
Biﬁ  dobacterium infantis and 
Streptococcus thermophilus
Florastar, Ultra Levure Saccharomyces boulardii
Flora Q Lactobacillus acidophilus, 
Lactobacillus paracasei, 
Biﬁ  dobacterium, 
S. thermophilus
Yakult ( Japan) Lactobacillus GGBiologics: Targets & Therapy 2008:2(3) 370
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environment and remain functionally unaltered on arrival 
to the site.
As mentioned earlier, in order for any microorganism 
be able to stimulate the gut immune system, for instance 
probiotic bacteria, they should be resistant to the enzymes in 
the oral cavity (amylases and lysozyme), to the low acidic pH 
in the stomach and to the presence of bile acids, pancreatic 
juice and mucus in the small intestine. These properties 
are important for survival in the small and large bowel. 
Micro-organisms must also be able to persist within the 
GIT and to adhere to gut epithelial tissue. Another important 
consideration expressed in the probiotic deﬁ  nition is the 
one concerned with the viability of the micro-organisms 
(Galdeano and Perdigon, 2004). Although Ouwehand and 
Salminen (1998) received interesting results while working 
on treatment for acute diarrhea suggesting that in some 
cases nonviable bacteria are able to produce effects similar 
to those obtained with viable bacteria, these ﬁ  ndings need 
to be further explored and proven effective in treatment of 
other diseases.
The principle of microencapsulation, 
its design and potentials in live 
biotherapeutics delivery
Cell microencapsulation consists of enclosing cells, such as 
primary cells, cell lines and genetically engineered cells to 
secrete therapeutic product in a semipermeable membrane 
(Chang and Prakash 1997). It is a process by which a 
liquid or solid active ingredient (encapsulated material) is 
packaged within an inert material (encapsulant) to protect 
the microencapsulated materials from the surrounding envi-
ronment, or conversely to protect the environment from the 
active ingredient. Artiﬁ  cial cells refer to manmade micro-
scopic structures that possess some functional properties of 
biological cells. The membrane allows bidirectional diffusion 
of nutrients, oxygen, metabolites, and waste but prevents high 
molecular weight substances, such as antibodies and immu-
nocytes, from entering the microcapsule, which provides an 
immune protection for the cells. Microcapsule membrane 
can be made of natural (alginate, arabinoglycan, chitosan, 
agarose, poly-L-lysine, xylan and collagen) or synthetic 
polymers (polyaminoacids, polyacrylates, chondroitin 
sulfate, cyclodextrin) (Zhang et al 2006). Other plant-derived 
polysaccharides, such as amylase, inulin, pectin and guar 
gum are known to remain unaffected in the presence of GI 
enzymes which enable the way for the formulation of the 
colon targeted delivery systems (Chourasia and Jain,2003). 
APA microencapsulation is one of the most well-studied 
encapsulation technologies, including entrapment of cells 
in alginate gel beads, formation of alginate-poly-L-lysine 
membrane, and liquefying of the alginate gel core to leave 
the cell ﬂ  oating in the center of the microcapsule (Ma 1994). 
Studies show that APA encapsulation yields intact capsules 
that preserve their integrity and are able to retain live bacterial 
cells (Urbanska et al 2006) (Figure 2). Moreover, genetically 
engineered bacteria have been encapsulated and used in oral 
therapy (Prakash and Chang 1996, 2000).
Cell microencapsulation is one of the promising 
strategies for the in vitro production of proteins or in vivo 
delivery of therapeutic products (Wen-tao et al 2006). In 
addition to in vitro culture, implantation of microencapsu-
lated cells represents a promising strategy for the controlled, 
localized, and long-term in vivo delivery of therapeutic 
products to the hosts (Orive et al 2003a). Bioencapsulation 
has provided a range of promising therapeutic treatments 
for diabetes (Sun et al 1996), hemophilia (Hortelano et al 
1996), cancer (Xu et al 2002), and renal failure (Prakash and 
Chang 1996). Although it might not serve yet as a replace-
ment technology to existing treatment modalities, it surely 
can serve as an alternative method should present ones fail. 
Today, with its potential and greatly increasing interest, 
the ﬁ  eld of microencapsulation should shortly receive an 
extensive scrutinization which will shortly allow its applica-
tion as a complementary treatment method to already well 
established methods.
Methods of live biotherapeutics cell 
delivery
Microencapsulation technology raises great potential 
in delivery of biotherpeutics live cells in medicine and 
biotechnology. In order to maintain microencapsulated 
cultures properties, it needs to be enclosed in a system 
that provides optimal conditions for their viability targeted 
delivery and functionality. The microcapsules preparation 
include physical methods like: pan coating, air-suspension 
coating, centrifugal extrusion, vibrational nozzle, spray-
drying and chemical methods like: interfacial polymerization, 
in situ polymerization, matrix polymerization.
Oral artiﬁ  cial bacterial cell therapy is a therapy which 
is based on oral delivery of live bacterial cells which are 
enclosed in artiﬁ  cial polymeric membrane. Clinical trials 
suggest potential beneﬁ  cial effects of probiotic therapy for 
preventing and treating antibiotic-associated diarrhea, acute 
diarrhea including rotavirus-induced diarrhea, traveler’s 
diarrhea, and diarrhea-predominant IBS. The most 
extensively studied probiotics for diarrhea are Lactobacillus, Biologics: Targets & Therapy 2008:2(3) 371
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Bifidobacterium and Saccharomyces, with potential 
mechanisms of therapeutic action based on the protection 
of intestinal epithelial cell and barrier function, prevention 
of enterotoxin binding to intestinal epithelial cells, and 
regulation of intestinal microbial environment (Yan and Polk 
2006). The release patterns include: pressure, shear stress, 
melting, dissolving, solvents, enzymes, chemical reactions, 
hydrolysis, slow disintegration, and pH.
The mathematical models have been built for animal 
cell growth, tumor cell growth (Quaranta et al 2005), such 
as Gompertzian growth, logistic growth, or exponential 
growth law (Retsky et al 1990). Various systems are listed 
in Table 4. Microencapsulation is a suitable technique to 
deliver various biotheraputics to a wide spectrum of cells 
and tissues enhancing the potential applicability of this 
strategy. Numerous applications include pharmaceuticals, 
dyes, agrochemicals, flavors and fragrances and other 
commercial possibilities.
Conclusions and future perspectives
At the start of the 21st century, research is poised at the 
interphase where artiﬁ  cial cells now range from macrodi-
mensions, to microndimensions, to nano-dimensions, and 
to molecular dimensions. Cell encapsulation represents an 
alternative non-viral approach for the long term delivery 
of therapeutic products. A comprehensive review covering 
delivery of live bacterial cells has been published by Prakash 
and Jones (2005).
Another review outlining the safety of current probiotic 
compounds has been published (Borriello et al 2003). 
Cases of infection due to lactobacilli and biﬁ  dobacteria 
are extremely rare, and are estimated to occur at a rate of 
approximately 0.05%–0.4% of all cases of infective endo-
carditis and bacteremia (Borriello et al 2003). No increase 
in bacteremia caused by Lactobacillus species was seen 
in Finland over the period from 1999 to 2000, despite an 
increased consumption of Lactobacillus rhamnosus GG 
(Isolauri et al 2002). Nevertheless, case reports have identi-
ﬁ  ed fungemia in two immunosuppressed patients (Riquelme 
et al 2003) and exacerbation of diarrhea in two patients with 
UC (Candelli et al 2003) who consumed Saccharomyces 
boulardi. Few other case reports have been published of 
infection caused after use of probiotics, like development 
of sepsis in premature neonates with short gut syndrome 
and chronic intestinal inﬂ  ammation after consumption of 
Lactobacillus GG (Kunz et al 2004). Also Lactobacillus 
rhamnosus infection cases have been reported in elderly 
patients, a 74-year-old woman (Rautio et al 1999) and a 
67-year-old man (Mackay et al 1999) who developed a liver 
abscess and tooth infection, respectively. The advantages 
of oral administration may result in the popularization of 
this mode of therapy once more data is produced about the 
incorporation of biologically active agents such as bacteria 
in therapeutics or advanced food systems and once it has 
been shown such option is safe and efﬁ  cient.
So far, the current data is promising and raises hopes 
in medicine and biotechnology. However, the amount of 
clinical trials is still insufﬁ  cient to conclude the overall 
safety of probiotic strains and other biotherapeutics use in 
therapy. Much work is still needed to exploit these beneﬁ  ts 
and to increase our understanding of their mechanisms, for 
instance improvement of microcapsule membrane designs, 
methods for improved cell harvest, the mass production of 
artiﬁ  cial cell microcapsules and the overall cost effective 
storage and clinical efﬁ  cacy. Nevertheless, the already 
available data suggests that only time and additional high 
quality outcome studies are needed to yield more promising 
and convincing results. Ultimately, the efﬁ  cacy, long-term 
                      (A)                                          (B)                                       (C) 
Figure 2 (a) Photomicrograph of freshly prepared empty APA microcapsules.
(Magniﬁ  cation 6.3x). (b) Photomicrograph of freshly prepared APA microcapsules loaded with L. acidophilus. (Magniﬁ  cation: 2.5x). (c) Photomicrograph of APA microcapsules 
loaded with L. acidophilus cells after 76 hours of incubation in MRS broth and 150 rpm in-vitro shaking at 37 ºC (Magniﬁ  cation: 6.3x)180.Biologics: Targets & Therapy 2008:2(3) 372
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Table 4 Microcapsule membrane systems features
Delivery vehicles Features Reference
Alginate-poly-L-lysine-alginate –   Most studied system for encapsulation of living cells
–   Formed by immersion of the calcium alginate beads 
in an aqueous solution of poly–L–lysine
–  Allows for proliferation of encapsulated cells and 
prolongs the survival of xeno–graphs implanted 
both intraperitoneally and subcutaneously
–   Used for encapsulated cells in industry, medicine, 
and agriculture, production of ethanol by yeast, 
lactic acid by lactic acid bacteria, monoclonal 
antibodies by hybridoma cells
– Tested in gene, cell and enzyme therapies
–   Simple and safe encapsulation procedure at 
physiological conditions
–   Long–term in vivo applications cause graft failures
Ma 1994; Prakash and Chang, 1996, 2000; 
Klinkenberg et al 2001; Rokstad et al 2002; 
van Raamsdonk et al 2002; Strand et al 2003; 
de Groot et al 2004; Urbanska et al 2006
Alginate-agarose microcapsules – Cell survival dependent on cell lines
–  Viability maintained for more than 70 days with no 
aggregates formation
– Mechanical stability compromised
Orive et al 2003a
Alginate-chitosan (AC) 
microcapsules
– Low cost
– Sturdier membrane than APA
–   Improved mechanical stability and reduced cell 
leakage
–   Suitable for mammalian and microbial cell growth 
and functions
Bartkowiak and Hunkeler 1999; Gaserod 
et al 1999; Serp et al 2000; Orive et al 2005
Genipin cross-linked AC 
microcapsules
–   Covalent link created by naturally occurring genipin
– Enhanced membrane strength and durability
Chen et al 2005, 2006a, 2006b
Alginate-PMCG-alginate capsules – Improved membrane strength
– Easily adjusted capsule size and wall thickness
– Oligomeric PMCG may be cytotoxic
(Orive et al 2003b)
Alginate-cellulose sulfate-poly-
(methylene-co-guanidine) 
(A-CS-PMCG) system
– Improved mechanical strength
– Easy control over membrane thickness
– Oligomeric PMCG may be immunogenic
– Yet to test long–term stability
Brissova et al 1998; Lacik et al 1998; Nurdin 
et al 2000; Bucko 2005; Bucko et al 2006
Polyvinlyamine hydrochloride-based 
microcapsules
– Mechanically stable
–   Permeability can be controlled over a wide range
Grigorescu et al 2002
PHEMA-MMA system – Water insoluble
–   Better stability and durability
–   Limited cell survival and mass transfer in some 
applications
Sefton et al 2000;   Vallbacka et al 2001; 
Kovacs-Nolan and Mine 2005
Chitosan core-poly 
(MAA-HEMA-MMA) shell
– Prepared in physiological conditions
–   Controllable mechanical strength and permeability
– Supported hepatocytes growth
– Maintained cell functions
Zhu et al 2005
Collagen core complexed with 
terpolymer HEMA-MAA-MMA-shell
–   Improved mechanical strength and chemical 
stabilizing
– Enhanced cell functions
Chia et al 2002; Yin et al 2003; Quek 
et al 2004
Sodium cellulose sulfate and poly 
(dimethyldiallylammonium chloride) 
system (NaCD-PDMDAAC)
–   MWCO less than 2 KD if prepared by standard 
method addition of pore forming agent (starch)
– Increased cutoff to 70 KD for protons
–  Allowed secretion and release of therapeutics by 
the encapsulated cells.
Dautzenberg et al 1999a, 1999b; Mei and Yao, 
2002; Zhang et al 2005; Yao et al 2006Biologics: Targets & Therapy 2008:2(3) 373
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safety and cost effectiveness of these therapies will prove 
their worth.
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